4basebio and TriLink Advance Phase I Cell Therapy Program
CAMBRIDGE, UK — September 28, 2026 4basebio PLC announced a collaboration with TriLink BioTechnologies, part of Maravai LifeSciences, to...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, UK — September 28, 2026 4basebio PLC announced a collaboration with TriLink BioTechnologies, part of Maravai LifeSciences, to...
Heidelberg, Germany, September 24, 2026 Flen Health has selected AGC Biologics as its contract development and manufacturing organization (CDMO)...
Yantai, China — September 7, 2026 CelluPro, Ltd. announced that it has received EXCiPACT™ GMP Certification for Pharmaceutical Auxiliary...
Albuquerque, New Mexico, September 3, 2026 Curia Global, Inc., a global contract research, development and manufacturing organization, has announced...
Edmonton, Alberta, Canada, September 2, 2026 Aurora Cannabis Inc., a global medical cannabis company, has urged its shareholders to...
Melbourne, Australia and Indianapolis, Indiana, U.S. | August 20, 2026 Telix Pharmaceuticals reported strong first-half 2026 performance, highlighting continued...
Chicago, Illinois, August 18, 2026 VectorBuilder and Lir Therapeutics have announced a strategic collaboration to advance adeno-associated virus (AAV)...
San Diego, California, August 5, 2026 NueCell Bio has officially launched as a specialized cell therapy science and development...
HAVERHILL, United Kingdom, July 6, 2026 Codis announced an agreement to acquire Catalent Pharma Solutions’ Nottingham, UK facility, a...
HOUSTON, June 16, 2026 FibroBiologics announced that the first patients have been dosed in its ongoing Phase 1/2 clinical...
